Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation

Lucinda A. Harris, Michael D. Crowell

Research output: Contribution to journalReview article

30 Scopus citations


Microbia Inc is developing the oral guanylate cyclase C agonist linaclotide, a 14mer peptide for the potential treatment of constipation- predominant irritable bowel syndrome and chronic idiopathic constipation. Phase II clinical trials are underway for both indications.

Original languageEnglish (US)
Pages (from-to)403-410
Number of pages8
JournalCurrent Opinion in Molecular Therapeutics
Issue number4
StatePublished - Aug 1 2007


ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Cite this